A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Inclusion Criteria: * Histologically confirmed persistent or recurrent ovarian epithelial, fallopian tube, or primary peritoneal carcinoma, including any of the following epithelial cell types: * Serous adenocarcinoma * Endometrioid adenocarcinoma * Mucinous adenocarcinoma * Undifferentiated carcinoma * Clear cell adenocarcinoma * Mixed epithelial carcinoma * Transitional cell carcinoma * Malignant Brenner tumor * Adenocarcinoma not otherwise specified * Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension as ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan * Must have ≥ 1 target lesion to assess response as defined by RECIST criteria * Tumors within a previously irradiated field are designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence of disease ≥ 90 days following completion of radiotherapy * Must not be eligible for a higher priority GOG clinical trial, if one exists (i.e., any active GOG Phase III clinical trial for the same patient population) * Must have received 1 prior platinum-based chemotherapeutic regimen containing carboplatin, cisplatin, or another organoplatinum compound for management of primary disease * Initial treatment may have included high-dose therapy, consolidation therapy, non-cytotoxic therapy, or extended therapy administered after surgical or non-surgical assessment * One additional cytotoxic regimen for management of recurrent or persistent disease allowed * Patients who have received only one prior cytotoxic regimen (platinum-based regimen for management of primary disease) must have a platinum-free interval of \< 12 months, have progressed during platinum-based therapy, or have persistent disease after a platinum-based therapy * GOG performance status 0-2 (for patients who received 1 prior regimen) OR 0-1 (for patients who received 2 prior regimens) * ANC ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Creatinine ≤ 1.5 times upper limit of normal (ULN) * Bilirubin ≤ 1.5 times ULN * SGOT ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Able and willing to self-administer daily subcutaneous (SC) injections or has a caregiver who is willing and able to administer daily SC injections * No active infection requiring antibiotics, except uncomplicated urinary tract infection * No neuropathy (sensory and motor) \> grade 2, according to CTCAE v3.0 * No other invasive malignancies within the past 5 years, except for non-melanoma skin cancer * No history of sensitivity to A6 * No active gastrointestinal bleeding within the past month * No other disease that, in the opinion of the investigator, could jeopardize patient safety or interfere with study objectives * No concurrent amifostine or other protective reagents * Recovered from prior surgery, radiotherapy, or chemotherapy * No prior non-cytotoxic therapy for management of recurrent or persistent disease * Prior biologic (non-cytotoxic) therapy as part of primary treatment regimen allowed * At least 1 week since prior hormonal therapy directed at the malignant tumor * At least 3 weeks since any other prior therapy directed at the malignant tumor, including immunological agents * More than 2 weeks since prior major surgical procedure * More than 5 years since prior radiotherapy to any portion of the abdominal cavity or pelvis other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer * More than 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin AND remains free of recurrent or metastatic disease * Patients with ductal breast carcinoma in situ may have undergone localized radiotherapy within the past 3 years * More than 5 years since prior chemotherapy for any abdominal or pelvic tumor other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer * More than 3 years since prior adjuvant chemotherapy for localized breast cancer AND remains free of recurrent or metastatic disease * More than 30 days since prior investigational drugs * No prior A6 * No prior radiotherapy to \> 25% of marrow-bearing areas * No prior cancer treatment that would contraindicate study therapy